株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

米国のメディカルアフェアーズの評価:2型糖尿病 (T2DM)

Medical Affairs Reputations (US): Type 2 Diabetes Mellitus

発行 FirstWord 商品コード 344323
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
米国のメディカルアフェアーズの評価:2型糖尿病 (T2DM) Medical Affairs Reputations (US): Type 2 Diabetes Mellitus
出版日: 2015年09月01日 ページ情報: 英文
概要

当レポートでは、2型糖尿病 (T2DM) 治療薬の主要10製品に関連するメディカルアフェアーズ (MA) チームについて米国国内の医師100名を対象に調査し、もっとも重要と考えるMAによる提供内容、もっとも尊重されているMAチームと他チームとの違い、MAによる提供内容への満足度、好みの伝達手段、改善の機会などについてまとめています。

調査内容

  • MAが提供するもっとも価値のある内容とは?
  • もっとも尊重されているMAチームとは?他のチームとの違いとは?
  • MAから必要な情報を十分に得られているか・好みの伝達手段は?
  • 貴社が利用するMAチームと競合チームとの違いとは?
  • 貴社のMAチームが成功している場所とは?改善の機会は?

調査対象製品

  • AstraZeneca
    • Forxiga (ダパグリフロジン)
  • Boehringer Ingelheim
    • Jardiance (エンパグリフロジン)
  • Eli Lilly
    • Trulicity (デュラグルチド)
  • GlaxoSmithKline
    • Eperzan (アルビグルチド)
  • Johnson & Johnson
    • Invokana (カナグリフロジン)
  • Merck & Co.
    • Januvia (シタグリプチンリン)
  • Novartis
    • Galvus (ビルダグリプチン)
  • Novo Nordisk
    • Tresiba (インスリンデグルデク)
  • Sanofi
    • Toujeo (インスリングラルギン)
  • 武田薬品工業
    • Vipidia (アログリプチン)
目次
Product Code: 596200407

What do physicians think of U.S. Medical Affairs teams in the Type 2 Diabetes Mellitus (T2DM) sector? Who gets top marks for performance and reputation? Who fails to measure up? How is your Medical Affairs team impacting your relationship with customers?

To find out, we surveyed 100 physicians from across the country regarding ten leading T2DM products and their associated Medical Affairs teams.

What did they have to say about your team? Are you lagging or leading your competitors? Order your report now to find out.

Note that in addition to the U.S. report we offer an equivalent report for Europe. Order both and receive, at no cost, a third report clearly setting out the differences in findings between the two regions.

Key Questions Answered:

  • What Medical Affairs offerings do physicians most value, and how well is your team providing them?
  • Whose Medical Affairs teams are most respected, and how exactly do they distinguish themselves from the pack?
  • Do physicians feel they hear from your Medical Affairs team as much as they'd like to, and what media and methods do they prefer?
  • What does gap analyses reveal about your Medical Affairs team versus your competitors?
  • Where is your Medical Affairs team succeeding and where are there opportunities for improvement?

Emerging Themes:

Medical Affairs teams in T2DM are generally well received, but physicians do have several recommendations for improvement; we provide the details.

Some Medical Affairs offerings are highly desired by physicians. Others generate much less interest. We let you know where your team might make adjustments and strengthen relationships as a result.

The products leading in the marketplace don't necessarily lead in Medical Affairs. Which teams are doing their T2DM products justice? Which might be dragging them down?

This report lets you know.

Products Included in the Report:

  • AstraZeneca
    • Forxiga (dapagliflozin)
  • Boehringer Ingelheim
    • Jardiance (empagliflozin)
  • Eli Lilly
    • Trulicity (dulaglutide)
  • GlaxoSmithKline
    • Eperzan (albiglutide)
  • Johnson & Johnson
    • Invokana (canagliflozin)
  • Merck & Co.
    • Januvia (sitagliptin)
  • Novartis
    • Galvus (vildagliptin)
  • Novo Nordisk
    • Tresiba (insulin degludec)
  • Sanofi
    • Toujeo (insulin glargine)
  • Takeda
    • Vipidia (alogliptin)
Back to Top